Vir Biotechnology (VIR) Equity Average (2018 - 2026)

Vir Biotechnology's Equity Average history runs 9 years deep, the most recent figure standing at $789.0 million for Q1 2026.

• In Q1 2026, Equity Average fell 28.08% year-over-year to $789.0 million; the TTM figure through Mar 2026 stood at $789.0 million (down 28.08% YoY), while the FY2025 annual figure was $957.8 million, down 30.1% from the prior year.
• Equity Average came in at $789.0 million for Q1 2026 at Vir Biotechnology, up from $780.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $2.1 billion in Q4 2022 to a low of $780.7 million in Q4 2025.
• A 5-year average of $1.5 billion and a median of $1.6 billion in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average jumped 184.74% in 2022 and sank 34.81% in 2025, its largest moves.
• Vir Biotechnology's Equity Average stood at $2.1 billion in 2022, then decreased by 22.77% to $1.6 billion in 2023, then slipped by 26.77% to $1.2 billion in 2024, then sank by 34.7% to $780.7 million in 2025, then rose by 1.07% to $789.0 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $789.0 million, $780.7 million, and $871.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison